Atria Wealth Solutions Inc. Sells 1,610 Shares of Zoetis Inc. (NYSE:ZTS)

Atria Wealth Solutions Inc. decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 10.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,109 shares of the company’s stock after selling 1,610 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Zoetis were worth $2,299,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. Hancock Whitney Corp increased its position in shares of Zoetis by 0.3% during the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after purchasing an additional 61 shares during the last quarter. Strategy Asset Managers LLC raised its position in Zoetis by 3.5% during the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after acquiring an additional 62 shares in the last quarter. VeraBank N.A. lifted its stake in Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after acquiring an additional 62 shares during the last quarter. Procyon Advisors LLC grew its position in shares of Zoetis by 1.4% in the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after acquiring an additional 63 shares during the period. Finally, Aberdeen Wealth Management LLC increased its stake in shares of Zoetis by 1.9% during the 3rd quarter. Aberdeen Wealth Management LLC now owns 3,566 shares of the company’s stock worth $697,000 after purchasing an additional 68 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 1.9 %

ZTS stock opened at $160.39 on Friday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The stock has a market capitalization of $71.82 billion, a price-to-earnings ratio of 29.32, a PEG ratio of 2.77 and a beta of 0.90. The business’s fifty day moving average price is $166.51 and its two-hundred day moving average price is $178.04.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.25%. Zoetis’s payout ratio is 36.56%.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ZTS has been the subject of several recent analyst reports. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Barclays increased their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, Piper Sandler reduced their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $214.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.